Skip to main content
. 2022 May 16;132(10):e145889. doi: 10.1172/JCI145889

Figure 4. Kisspeptin analog treatment protects against insulin resistance and hepatic steatosis in HFD-fed mice.

Figure 4

Blood glucose levels during (A) fasting, (B) GTT (2.5 weeks on treatment), and (C) ITT (3.5 weeks on treatment). KPA, kisspeptin agonist. (D) Basal insulin levels. (E) Representative histology of H&E- (left) and Oil Red O–stained (right) liver sections, showing lipid accumulation (red). Quantification of staining is shown. Scale bars: 200 μm. (F–K) Endpoint (11 weeks on diet) measurements of (F) hepatic triglycerides (TGs) and (G) serum TGs, (H) FFA, (I) glycerol, (J) cholesterol, and (K) ALT levels (5 weeks on treatment). (L) Expression of indicated genes by RT-qPCR. Data are shown as the mean ± SEM. Student’s unpaired t test or 1-way ANOVA followed by Dunnett’s post hoc test. *P < 0.05 versus respective controls.